Ligand Targretin
Executive Summary
Cutaneous T-cell lymphoma therapy bexarotene will be reviewed by FDA's Oncologic Drugs Advisory Committee in December, according to Chief Financial Officer Paul Maier. The committee has a meeting scheduled for December 13-14